Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65,833,370
-
Total 13F shares
-
27,785,042
-
Share change
-
+23,823,685
-
Total reported value
-
$356,422,494
-
Put/Call ratio
-
27%
-
Price per share
-
$13.00
-
Number of holders
-
61
-
Value change
-
+$311,412,812
-
Number of buys
-
46
-
Number of sells
-
13
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q2 2020
As of 30 Jun 2020 Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) had 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 27,785,042 shares of stock of the company.
Largest 10 holders included BVF INC/IL, RTW INVESTMENTS, LP, Logos Global Management LP, Redmile Group, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Ikarian Capital, LLC, RENAISSANCE TECHNOLOGIES LLC, Vivo Capital, LLC, VANGUARD GROUP INC, and RA CAPITAL MANAGEMENT, L.P..
This table shows 62 institutional shareholders of the security as of 30 Jun 2020.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.